Neuroblastoma is cancer most commonly affects children age of 5 or younger, and rarely occur in older children. It develops from immature nerve cells found in several areas of the body. It most commonly arises in and around the adrenal glands, which have similar origins to nerve cells and sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the neck, chest, and near the spine, where groups of nerve cells exist. Some forms of neuroblastoma go away on their own, while others may require various treatments. There are different types of treatments are available such as combination chemotherapy, monoclonal antibody therapy, vaccine therapy, and others. The rising incidences of cancer worldwide is one of the major factor contributing to the growth of the market. Also, Stay up-to-date with latest research insights on "Pediatric Neuroblastoma Treatment Share & Growth Analysis
Highlights from Neuroblastoma Treatment Market Study
|Largest Market||North America|
|Forecast Value (2027)||USD 1.25 Billion|
|Unit||Value (USD Billion)|
The key Players profiled in the report are Seattle Children’s (United States), CureSearch (United States), Texas Children’s (United States), NANT (United States), The Children’s Hospital of Philadelphia (United States), Boston Children's Hospital (United States), Children’s Oncology Group (United States), Memorial Sloan Kettering Cancer Center (United States), UCSF Benioff Children's Hospital (United States) and The Royal Marsden (United Kingdom). Additionally, other players that are part of this comprehensive study are St. Jude Children's Research Hospital (United States), Apollo Hospitals Enterprise Ltd. (India) and Max Healthcare (India).
Geographic Breakdown and Segment Analysis
The Global Neuroblastoma Treatment market presents a comprehensive analysis of the Neuroblastoma Treatment market by product type (Chemotherapy), by end-user/application (Hospitals, Clinics and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Neuroblastoma Treatment industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the North America holds majority of market share of the Neuroblastoma Treatment market
Analyst at AMA have segmented the market study of Global Neuroblastoma Treatment market by Type, Application and Region. On the basis of Type, Combination Chemotherapy are dominating the market in the year 2021.
Neuroblastoma Treatment Market Dynamics:
- The Rising Incidences of Cancer Worldwide
- Growing Healthcare Expenditure among the Globe
- Increased Cancer Research and Development Activities
- Rise in the Awareness about Cancer Treatment among People
- A High cost of the Treatment
|Gaps & Opportunities|
- The Increasing Incidences of Neuroblastoma from Developing Regions
- Medical Tourism Can Open New Avenues for the Neuroblastoma Treatment Providers
Market Developments Activities:
Recently, researchers at Sahlgrenska Academy in Gothenburg and Karolinska Institute, among others, have identified two new significant biomarkers for childhood cancer neuroblastoma. and On 29 Nov. 2018, United Therapeutics Corporation has announced that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations
Key Target Audience
Neuroblastoma Treatments Provider, Research Institutes, Regulatory & Government Bodies, Industry Associations, End Users and Others